151 related articles for article (PubMed ID: 12100136)
1. Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor.
Kanda Y; Tanosaki R; Nakai K; Saito T; Ohnishi M; Niiya H; Chizuka A; Yakushijin K; Urahama N; Ueda K; Iijima K; Ando T; Matsubara H; Kami M; Makimoto A; Kobayashi Y; Tobinai K; Mineishi S; Takaue Y
Br J Haematol; 2002 Jul; 118(1):128-31. PubMed ID: 12100136
[TBL] [Abstract][Full Text] [Related]
2. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility.
Bolan CD; Childs RW; Procter JL; Barrett AJ; Leitman SF
Br J Haematol; 2001 Mar; 112(3):787-95. PubMed ID: 11260085
[TBL] [Abstract][Full Text] [Related]
3. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.
Maciej Zaucha J; Mielcarek M; Takatu A; Little MT; Gooley T; Baker J; Maloney DG; Sandmaier BM; Maris M; Chauncey T; Storb R; Torok-Storb B
Br J Haematol; 2002 Dec; 119(3):740-50. PubMed ID: 12437653
[TBL] [Abstract][Full Text] [Related]
4. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation.
Wäsch R; Bertz H; Kunzmann R; Finke J
Br J Haematol; 2000 Jun; 109(4):743-50. PubMed ID: 10929024
[TBL] [Abstract][Full Text] [Related]
5. [Multiple factors in erythrocytic recovery following ABO-incompatible allogeneic HSCT].
Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):812-5. PubMed ID: 15631667
[TBL] [Abstract][Full Text] [Related]
6. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Schuler US; Renner UD; Kroschinsky F; Johne C; Jenke A; Naumann R; Bornhäuser M; Deeg HJ; Ehninger G
Br J Haematol; 2001 Sep; 114(4):944-50. PubMed ID: 11564090
[TBL] [Abstract][Full Text] [Related]
7. Restricted usage of T-cell receptor alpha-chain variable region (TCRAV) and T-cell receptor beta-chain variable region (TCRBV) repertoires after human allogeneic haematopoietic transplantation.
Matsutani T; Yoshioka T; Tsuruta Y; Iwagami S; Toyosaki-Maeda T; Horiuchi T; Miura AB; Watanabe A; Takada G; Suzuki R; Hirokawa M
Br J Haematol; 2000 Jun; 109(4):759-69. PubMed ID: 10929026
[TBL] [Abstract][Full Text] [Related]
8. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
Hefazi M; Litzow M; Hogan W; Gastineau D; Jacob E; Damlaj M; Hashmi S; Al-Kali A; Patnaik MM
Transfusion; 2016 Feb; 56(2):518-27. PubMed ID: 26446051
[TBL] [Abstract][Full Text] [Related]
9. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation.
Benjamin RJ; McGurk S; Ralston MS; Churchill WH; Antin JH
Transfusion; 1999 Feb; 39(2):179-87. PubMed ID: 10037129
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
[TBL] [Abstract][Full Text] [Related]
11. Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate.
Gajewski JL; Petz LD; Calhoun L; O'Rourke S; Landaw EM; Lyddane NR; Hunt LA; Schiller GJ; Ho WG; Champlin RE
Blood; 1992 Jun; 79(11):3076-85. PubMed ID: 1586749
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
13. Anthracyclines added to the conditioning regimen for allogeneic bone marrow transplantation are associated with a slower haematopoietic recovery.
Van der Lely N; De Witte T; Raemaekers J; Schattenberg A; Haanen C
Bone Marrow Transplant; 1989 Mar; 4(2):163-6. PubMed ID: 2650786
[TBL] [Abstract][Full Text] [Related]
14. [Effect of ABO-incompatibility on allogeneic hematopoietic stem cell transplantation].
Bao L; Huang XJ; Liu KY; Xu LP; Chen H; Zhang YC; Chen YH; Han W; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 37(2):126-9. PubMed ID: 15841137
[TBL] [Abstract][Full Text] [Related]
15. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.
Blin N; Traineau R; Houssin S; Peffault de Latour R; Petropoulou A; Robin M; Larghero J; Ribaud P; Socié G
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1315-23. PubMed ID: 20353831
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases.
Platzbecker U; Ehninger G; Schmitz N; Bornhäuser M
Ann Hematol; 2003 Aug; 82(8):463-468. PubMed ID: 12910373
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?
Gutiérrez-Aguirre CH; Gómez-De-León A; Alatorre-Ricardo J; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; Mancías-Guerra C; Flores-Jiménez JA; Gómez-Almaguer D
Transfusion; 2014 May; 54(5):1269-77. PubMed ID: 24898453
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience.
Stussi G; Seebach L; Muntwyler J; Schanz U; Gmür J; Seebach JD
Br J Haematol; 2001 Apr; 113(1):251-3. PubMed ID: 11328309
[TBL] [Abstract][Full Text] [Related]
19. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.
Watz E; Remberger M; Ringden O; Lundahl J; Ljungman P; Mattsson J; Wikman A; Uhlin M
Biol Blood Marrow Transplant; 2014 Feb; 20(2):264-71. PubMed ID: 24274982
[TBL] [Abstract][Full Text] [Related]
20. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Frassoni F; Sessarego M; Fugazza G; Di Stefano F; Pitto A; Bacigalupo A
Br J Haematol; 2000 Jun; 109(4):716-21. PubMed ID: 10929020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
